Trophoblast cell-surface antigen 2 (TROP2) expression in triple-negative breast cancer
Abstract Background Trophoblast cell-surface antigen 2 (TROP2) is related to tumor proliferation enhancement and poor prognosis. An antibody targeting TROP2 was developed to treat metastatic triple-negative breast cancer (TNBC) which has a limited treatment modality. To characterize the TROP2 expres...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-09-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-022-10076-7 |
| _version_ | 1818016673274265600 |
|---|---|
| author | Yeonjin Jeon Uiree Jo Jongmoo Hong Gyungyub Gong Hee Jin Lee |
| author_facet | Yeonjin Jeon Uiree Jo Jongmoo Hong Gyungyub Gong Hee Jin Lee |
| author_sort | Yeonjin Jeon |
| collection | DOAJ |
| description | Abstract Background Trophoblast cell-surface antigen 2 (TROP2) is related to tumor proliferation enhancement and poor prognosis. An antibody targeting TROP2 was developed to treat metastatic triple-negative breast cancer (TNBC) which has a limited treatment modality. To characterize the TROP2 expressing tumors in TNBC, we analyzed TROP2 expression in three cohorts; (1) primary tumor without neoadjuvant chemotherapy, (2) primary tumor with neoadjuvant chemotherapy, and (3) metastatic tumor. Methods A total of 807 TNBC cases were evaluated for TROP2 immunohistochemical expression. We evaluated the TROP2 H-score distribution in the three cohorts. Tumors were divided into two groups based on TROP2 expression (high vs. low). We analyzed the relationship between clinicopathologic features and markers, including epidermal growth factor receptor, cytokeratin 5/6, p53, and Ki-67, and prognostic significance at high vs. low TROP2 expression. Results There was no difference in TROP2 H-score distribution between the three cohorts. Moderate-to-strong membranous expression of TROP2 in at least 10% of tumor cells was present in 662 cases (82.0%) in Cohort 1, 59 cases (89.4%) in Cohort 2, and 23 cases (88.5%) in Cohort 3. There was no significant difference in clinicopathologic features between high vs. low TROP2 in all cohorts. TROP2 H-score was an independent poor prognostic factor for overall survival in Cohort 3. Conclusions TNBC showed similar TROP2 expression regardless of neoadjuvant treatment or primary tumor/metastasis. Although the prognostic significance of TROP2 expression in metastatic TNBC has been revealed, further evaluation of the predictive value of TROP2 expression for targeted therapy is needed. |
| first_indexed | 2024-04-14T07:15:56Z |
| format | Article |
| id | doaj.art-73c7e6c73b8040039748c23e930f9ffd |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-04-14T07:15:56Z |
| publishDate | 2022-09-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-73c7e6c73b8040039748c23e930f9ffd2022-12-22T02:06:18ZengBMCBMC Cancer1471-24072022-09-012211910.1186/s12885-022-10076-7Trophoblast cell-surface antigen 2 (TROP2) expression in triple-negative breast cancerYeonjin Jeon0Uiree Jo1Jongmoo Hong2Gyungyub Gong3Hee Jin Lee4Department of Pathology, University of Ulsan College of Medicine, Asan Medical CenterDepartment of Pathology, University of Ulsan College of Medicine, Asan Medical CenterBiomedical Sciences, Asan Medical Institute of Convergence Science and Technology (AMIST), Asan Medical Center, University of Ulsan College of MedicineDepartment of Pathology, University of Ulsan College of Medicine, Asan Medical CenterDepartment of Pathology, University of Ulsan College of Medicine, Asan Medical CenterAbstract Background Trophoblast cell-surface antigen 2 (TROP2) is related to tumor proliferation enhancement and poor prognosis. An antibody targeting TROP2 was developed to treat metastatic triple-negative breast cancer (TNBC) which has a limited treatment modality. To characterize the TROP2 expressing tumors in TNBC, we analyzed TROP2 expression in three cohorts; (1) primary tumor without neoadjuvant chemotherapy, (2) primary tumor with neoadjuvant chemotherapy, and (3) metastatic tumor. Methods A total of 807 TNBC cases were evaluated for TROP2 immunohistochemical expression. We evaluated the TROP2 H-score distribution in the three cohorts. Tumors were divided into two groups based on TROP2 expression (high vs. low). We analyzed the relationship between clinicopathologic features and markers, including epidermal growth factor receptor, cytokeratin 5/6, p53, and Ki-67, and prognostic significance at high vs. low TROP2 expression. Results There was no difference in TROP2 H-score distribution between the three cohorts. Moderate-to-strong membranous expression of TROP2 in at least 10% of tumor cells was present in 662 cases (82.0%) in Cohort 1, 59 cases (89.4%) in Cohort 2, and 23 cases (88.5%) in Cohort 3. There was no significant difference in clinicopathologic features between high vs. low TROP2 in all cohorts. TROP2 H-score was an independent poor prognostic factor for overall survival in Cohort 3. Conclusions TNBC showed similar TROP2 expression regardless of neoadjuvant treatment or primary tumor/metastasis. Although the prognostic significance of TROP2 expression in metastatic TNBC has been revealed, further evaluation of the predictive value of TROP2 expression for targeted therapy is needed.https://doi.org/10.1186/s12885-022-10076-7TROP2Triple-negative breast cancerOverall survival |
| spellingShingle | Yeonjin Jeon Uiree Jo Jongmoo Hong Gyungyub Gong Hee Jin Lee Trophoblast cell-surface antigen 2 (TROP2) expression in triple-negative breast cancer BMC Cancer TROP2 Triple-negative breast cancer Overall survival |
| title | Trophoblast cell-surface antigen 2 (TROP2) expression in triple-negative breast cancer |
| title_full | Trophoblast cell-surface antigen 2 (TROP2) expression in triple-negative breast cancer |
| title_fullStr | Trophoblast cell-surface antigen 2 (TROP2) expression in triple-negative breast cancer |
| title_full_unstemmed | Trophoblast cell-surface antigen 2 (TROP2) expression in triple-negative breast cancer |
| title_short | Trophoblast cell-surface antigen 2 (TROP2) expression in triple-negative breast cancer |
| title_sort | trophoblast cell surface antigen 2 trop2 expression in triple negative breast cancer |
| topic | TROP2 Triple-negative breast cancer Overall survival |
| url | https://doi.org/10.1186/s12885-022-10076-7 |
| work_keys_str_mv | AT yeonjinjeon trophoblastcellsurfaceantigen2trop2expressionintriplenegativebreastcancer AT uireejo trophoblastcellsurfaceantigen2trop2expressionintriplenegativebreastcancer AT jongmoohong trophoblastcellsurfaceantigen2trop2expressionintriplenegativebreastcancer AT gyungyubgong trophoblastcellsurfaceantigen2trop2expressionintriplenegativebreastcancer AT heejinlee trophoblastcellsurfaceantigen2trop2expressionintriplenegativebreastcancer |